Scafuro G, Nagatsuka T et al. miRNA-lncRNA Cross-Regulation Landscape in Cancer: From Molecular Mechanisms to Therapeutic and Diagnostic Applications. Cancers (Basel). 2026 May 15;18(10):1610.

Rahman AA, Ohishi K et al. Structural and functional gastrointestinal abnormalities in ACTA2 R179H mice modeling multisystemic smooth muscle dysfunction syndrome. JCI Insight. 2026 Jan 6;11(4):e190469.

Tahara T et al. Opposite effects of spermidine and GC7 in cell culture are dictated by distinct molecular targets. Biochem J. 2025 Dec 17;482(24):1973-1992.

Ureshino H, Ueshima T, Yamaguchi T, Takashima M, Sanuki Y et al. (R)-WAC-224, a new anticancer quinolone, combined with venetoclax and azacitidine overcomes venetoclax-resistant AML through MCL-1 downregulation. Sci Rep. 2025 May 8;15(1):16018.

Ohishi K et al. Resolving Resident Colonic Muscularis Macrophage Diversity and Plasticity During Colitis. Inflamm Bowel Dis. 2025 Jan 6;31(1):151-168.

Angabo S, Kawasaki H et al. CD47 and thrombospondin 1 contribute to immune evasion by Porphyromonas gingivalis. Proc Natl Acad Sci U S A. 2024 Nov;121(47):e2405534121.

Rahman AA, Ohishi K et al. Enteric neural stem cell transplant restores gut motility in mice with Hirschsprung disease. JCI Insight. 2024 Jul 23;9(17):e179755.

Yamamoto K, Kazamori D, Seo K et al. Development of a natural product optimization strategy for inhibitors against MraY, a promising antibacterial target. Nat Commun. 2024 Jun 14;15(1):5085.

Saba E, Kawasaki H et al. Oral bacteria accelerate pancreatic cancer development in mice. Gut. 2024 Apr 5;73(5):770-786.

Pan W, Ohishi K et al. Autologous cell transplantation for treatment of colorectal aganglionosis in mice. Nat Commun. 2024 Mar 20;15(1):2479.

Matsuzaki S et al. REMOVER-PITCh: microhomology-assisted long-range gene replacement with highly multiplexed CRISPR-Cas9. In Vitro Cell Dev Biol Anim. 2024 Aug;60(7):697-707.

Rahman AA, Ohishi K et al. Optogenetic activation of cholinergic enteric neurons reduces inflammation in experimental colitis. Cell Mol Gastroenterol Hepatol. 2024;17(6):907-921.

Guyer RA, Ohishi K et al. Differentiated neuroblastoma cells remain epigenetically poised for de-differentiation to an immature state. Dis Model Mech. 2023 Dec 1;16(12):dmm049754.

Mino T, Ueshima T, Kashimoto N, Yamaguchi T et al. A novel anticancer quinolone, (R)-WAC-224, has anti-leukemia activities against acute myeloid leukemia. Invest New Drugs. 2023 Oct;41(5):751-760.

Lemecha M, Takamuku Y et al. Lcn2 mediates adipocyte-muscle-tumor communication and hypothermia in pancreatic cancer cachexia. Mol Metab. 2022 Dec;66:101612.

Takashima M et al. Localized and systemic inflammatory mediators in a murine acute mastitis model. J Inflamm Res. 2021 Aug 21;14:4053-4067.

Kawasaki H, Amano H. Anti-inflammatory role of microRNA-429 in human gingival epithelial cells-inhibition of IL-8 production through direct binding to IKKβ mRNA. Mol Med Rep. 2021 Aug;24(2):581.

Okazaki Y et al. Increased glucose metabolism in Arid5b -/- skeletal muscle is associated with the down-regulation of TBC1 domain family member 1 (TBC1D1). Biol Res. 2020 Oct 6;53(1):45.

Kawasaki H, Takeuchi T et al. Definition of miRNA Signatures of Nodal Metastasis in LCa: miR-449a Targets Notch Genes and Suppresses Cell Migration and Invasion. Mol Ther Nucleic Acids. 2020 Jun 5;20:711-724.

Takeuchi T, Kawasaki H et al. Insight toward the MicroRNA Profiling of Laryngeal Cancers: Biological Role and Clinical Impact. Int J Mol Sci. 2020 May 24;21(10):3693.

Stasio DD, Kawasaki H et al. Salivary mir-27b Expression in Oral Lichen Planus Patients: A Series of Cases and a Narrative Review of Literature. Curr Top Med Chem. 2019;19(31):2816-2823.

Misso G, Kawasaki H et al. miR-125b Upregulates miR-34a and Sequentially Activates Stress Adaption and Cell Death Mechanisms in Multiple Myeloma. Mol Ther Nucleic Acids. 2019 Jun 7;16:391-406.

Kawasaki H et al. Determination of miRNAs from Cancer Stem Cells Using a Low Density Array Platform. Methods Mol Biol. 2018;1692:149-156.

Hirano T, Kinoshita T, Kazamori D, Inoue S, Nishimura K, Sakurai A, Ohishi K, Kuramoto Y, Amano H, Yazaki A. Discovery of a Novel Fluoroquinolone Antibiotic Candidate WFQ-228 with Potent Antimicrobial Activity and the Potential to Overcome Major Drug Resistance. Chem Pharm Bull (Tokyo). 2018 Mar 1;66(3):235-238.

Kitaoka S et al. FGT-1-mediated glucose uptake is defective in insulin/IGF-like signaling mutants in Caenorhabditis elegans. FEBS Open Bio. 2016 Apr 21;6(6):576-585.

Itoh K, Kuramoto Y, Amano H, Kazamori D, Yazaki A. Discovery of WQ-3810: Design, synthesis, and evaluation of 7-(3-alkylaminoazetidin-1-yl)fluoro-quinolones as orally active antibacterial agents. Eur J Med Chem. 2015 Oct 20;103:354-360.

Sakata K et al. Neovessel formation promotes liver fibrosis via providing latent transforming growth factor-β.Biochem Biophys Res Commun. 2014 Jan 17;443(3):950-6.

Tanaka K, Inoue S et al. A novel acylaminoimidazole derivative, WN1316, alleviates disease progression via suppression of glial inflammation in ALS mouse model. PloS One. 2014 Jan 31;9(1):e87728.

Doig P, Itoh K, Kinoshita T, Kuroda S, Sato T, Sugimoto K, Tohyama K, Aoi H, Wakamatsu K et al. Rational design of inhibitors of the bacterial cell wall synthetic enzyme GlmU using virtual screening and lead-hopping. Bioorg Med Chem. 2014 Nov 1;22(21):6256-6269.

Kazamori D, Aoi H, Sugimoto K, Ueshima T, Amano H, Itoh K, Kuramoto Y, Yazaki A. In vitro activity of WQ-3810, a novel fluoroquinolone, against multidrug-resistant and fluoroquinolone-resistant pathogens. Int J Antimicrob Agents. 2014 Nov;44(5):443-449.

Sakata K et al. HCV NS3 protease enhances liver fibrosis via binding to and activating TGF-β type I receptor. Sci Rep. 2013 Nov 22;3:3243.

Kitaoka S et al. FGT-1 is a mammalian GLUT2-like facilitative glucose transporter in Caenorhabditis elegans whose malfunction induces fat accumulation in intestinal cells. PLoS One. 2013 Jun 24;8(6):e68475.

Asano T, Yokomoto M, Misumi K, Kinoshita T et al. Identification, synthesis, and biological evaluation of 6-[(6R)-2-(4-fluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3(2H)-one (AS1940477), a potent p38 MAP kinase inhibitor. J Med Chem. 2012 Sep 13;55(17):7772-7785.

Miyata J, Nishimura K, Akamatsu H, Taguchi Y, Yamaguchi T et al. Orally available pyridinylpyrimidine derivatives as novel RANKL-induced osteoclastogenesis inhibitors. Bioorg Med Chem Lett. 2012 Sep 1;22(17):5681-5684.

Takahashi R et al. Structure and reaction mechanism of human nicotinamide phosphoribosyltransferase. J Biochem. 2010 Jan;147(1):95-107.

Toda A, Misumi K, Itoh K, Satoh K, Inoue S et al. Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: discovery of FR264205. Bioorg Med Chem Lett. 2008 Sep 1;18(17):4849-4852.

Murano K, Akamatsu H, Itoh K, Misumi K, Inoue S et al. Structural requirements for the stability of novel cephalosporins to AmpC β-lactamase based on 3D-structure. Bioorg Med Chem. 2008 Mar 1;16(5):2261-2275.

中沢隆, 高橋亮ほか. NMPRTase/PBEF/Visfatin:ホスホリボシル転移酵素の触媒機構と多機能性. 日本応用酵素協会誌. 2008;42:11-21.

Takahashi R et al. Crystallization of human nicotinamide phosphoribosyltransferase. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 May 1;63(5):375-377.

倉本康弘. 湧永製薬におけるニューキノロン系抗菌剤の創薬研究. MEDCHEM NEWS. 2007;17(2):2-7.

Oomizu S, Suzuki H et al. Fucoidan prevents C epsilon germline transcription and NFkappaB p52 translocation for IgE production in B cells. Biochem Biophys Res Commun. 2006 Nov 24;350(3):501-507.

Tanaka A, Suzuki H et al. Semi-purification of the immunoglobulin E-sweat antigen acting on mast cells and basophils in atopic dermatitis. Exp Dermatol. 2006 Apr;15(4):283-290.

Oomizu S, Suzuki H et al. Oral administration of pulverized Konjac glucomannan prevents the increase of plasma IgE and IgG levels induced by the injection of syngeneic keratinocyte extracts in BALB/c mice. Clin Exp Allergy. 2006 Jan;36(1):102-110.

Inokuma K et al. Indispensable role of mitochondrial UCP1 for antiobesity effect of beta3-adrenergic stimulation. Am J Physiol Endocrinol Metab. 2006 May;290(5):E1014-E1021.

Wang Y, Inokuma K et al. Potential contribution of vasoconstriction to suppression of heat loss and homeothermic regulation in UCP1-deficient mice. Pflugers Arch. 2006 Jun;452(3):363-369.

Kontani Y, Inokuma K et al. UCP1 deficiency increases susceptibility to diet-induced obesity with age. Aging Cell. 2005 Jun;4(3):147-155.

猪熊健一ほか. UCP1はβ3アドレナリン受容体アゴニストの抗肥満効果に必須である. 肥満研究. 2005;11(2):188-190.

Inokuma K et al. Uncoupling protein 1 is necessary for norepinephrine-induced glucose utilization in brown adipose tissue. Diabetes. 2005 May;54(5):1385-1391.

林則博. フルオロキノロン剤の光毒性に関する新たな構造－毒性相関と光安定性について. 薬学雑誌. 2005;125(3):255-261.

Hayashi N, Yazaki A et al. New findings on the structure-phototoxicity relationship and photostability of fluoroquinolones with various substituents at position 1. Antimicrob Agents Chemother. 2004 Mar;48(3):799-803.

Akamatsu H et al. Solid-Phase Synthesis of Indol-2-ones by Microwave-Assisted Radical Cyclization. Synlett. 2004;6:1049-1053.

Kuramoto Y, Ohshita Y, Yoshida J, Yazaki A et al. A novel antibacterial 8-chloroquinolone with a distorted orientation of the N1-(5-amino-2,4-difluorophenyl) group. J Med Chem. 2003 May 8;46(10):1905-1917.

金田幸, 梶村芳雄. 新規抗真菌抗生物質BacillopeptinsおよびFusaricidinsについて. 薬学雑誌. 2002;122(9):651-671.

Akamatsu H et al. New efficient route for solid phase synthesis of benzimidazole derivatives. J Comb Chem. 2002 Sep-Oct;4(5):475-483.

Akamatsu H et al. Reactivity switching on solid support: solid-phase synthesis of tertiary amines by reduction of tertiary amides with LiAlH4. Tetrahedron Lett. 2002 Dec 2;43(49):8867-8869.

Nakaizumi A, Oka T et al. Frequent multiple c-Ki-ras oncogene activation in pancreatic juice from patients with benign small pancreatic cysts. Digestive Endoscopy. 2001;13(2):77-81.

Tanaka T, Oka T, Ogawa T et al. Defect in human myocardial long-chain fatty acid uptake is caused by FAT/CD36 mutations. J Lipid Res. 2001 May;42(5):751-759.

Takai S, Sumi S, Aoike M et al. Characterization of recombinant human chymase expressed in Escherichia coli. Jpn J Pharmacol. 2000 Feb;82(2):144-149.

Nagao Y, Hirata T et al. Intramolecular nonbonded S･･･O interaction recognized in (acylimino)thiadiazoline derivatives as angiotensin II receptor antagonists and related compounds. J Am Chem Soc. 1998 Mar 20;120(13):3104-3110.

Kajimura Y, Kaneda M. Fusaricidins B, C and D, new depsipeptide antibiotics produced by Bacillus polymyxa KT-8: isolation, structure elucidation and biological activity. J Antibiot (Tokyo). 1997 Mar;50(3):220-228.

Tamura K, Okuhira M, Amano H, Inokuma K, Hirata T, Hashimoto K et al. Pharmacologic profiles of KRH-594, a novel nonpeptide angiotensin II-receptor antagonist. J Cardiovasc Pharmacol. 1997 Nov;30(5):607-615.

Tamura K, Okuhira M, Hashimoto K et al. In vitro pharmacological properties of KRH-594, a novel angiotensin II type 1 receptor antagonist. Biol Pharm Bull. 1997 Aug;20(8):850-855.

Hirata T, Tamura K, Okuhira M et al. Quantitative structure-activity relationships of benzoyliminothiadiazoline derivatives as andiotensin II receptor antagonists. Bioorg Med Chem Lett. 1997;7(4):385-388.

Hirata T et al. A facile synthesis of 2-acylimino-3-biphenylmethyl-1,3,4-thiasiazoline derivatives. Heterocycles. 1997;44(1):133-138.

Kajimura Y, Kaneda M. Fusaricidin A, a new depsipeptide antibiotic produced by Bacillus polymyxa KT-8. Taxonomy, fermentation, isolation, structure elucidation and biological activity. J Antibiot (Tokyo). 1996 Feb;49(2):129-135.

Kikuchi A, Fuwa T et al. Efficient gene transfer to EGF receptor overexpressing cancer cells by means of EGF-labeled cationic liposomes. Biochem Biophys Res Commun. 1996 Oct 23;227(3):666-671.

Hirata T, Nomiyama J, Sakae N, Nishimura K, Yokomoto M, Inoue S, Tamura K, Okuhira M, Amano H et al. Acyliminothiadiazoline derivatives: New, highly potent, and orally active angiotensin II receptor antagonists. Bioorg Med Chem Lett. 1996;6(13):1469-1474.

Kajimura Y et al. Bacillopeptins, new cyclic lipopeptide antibiotics from Bacillus subtilis FR-2. J Antibiot (Tokyo). 1995 Oct;48(10):1095-1103.

Ichikawa M, Fuwa T et al. Effect of perfusate pH on the influx of 5-5'-dimethyl-oxazolidine-2,4-dione and dissociation of epidermal growth factor from the cell-surface receptor: the existence of the proton diffusion barrier in the Disse space. J Hepatol. 1994 Feb;20(2):190-200.

Murakami T, Fuwa T et al. Dose-dependent plasma clearance of human epidermal growth factor in rats. J Pharm Sci. 1994 Oct;83(10):1400-1403.

Kyo E et al. Reduced tumorigenicity and cell motility of a gastric-carcinoma cell-line by introduction of wild-type p53 gene. Int J Oncol. 1993 Aug;3(2):265-271.

Wargovich MJ, Imada O. Esophageal carcinogenesis in the rat: a model for aerodigestive tract cancer. J Cell Biochem Suppl. 1993:17F:91-4.

Kiyohara Y, Fuwa T et al. Systemic effects of epidermal growth factor (EGF) ointment containing protease inhibitor or gelatin in rats with burns or open wounds. Biol Pharm Bull. 1993 Jan;16(1):73-76.

Murakami T, Amagase H, Fuwa T et al. Effect of absorption promoters on subcutaneous absorption of human epidermal growth factor in rats. J Pharm Sci. 1993 Mar;82(3):236-239.

Yokozaki H, Kyo E et al. Biologic effect of human hepatocyte growth-factor on human gastric-carcinoma cell-lines. Int J Oncol. 1993 Jul;3(1):89-93.

清水信行, 不破亨ほか. ブレオマイシンを封入したEGF修飾リポソームの受容体を介した殺細胞効果. Drug Deliv Syst. 1993 May;8(3):193-197.

Kitadai Y, Kyo E et al. GC factor represses transcription of several growth factor/receptor genes and causes growth inhibition of human gastric carcinoma cell lines. Cell Growth Differ. 1993 Apr;4(4):291-296.

Ito R, Kyo E et al. Interleukin 1 alpha acts as an autocrine growth stimulator for human gastric carcinoma cells. Cancer Res. 1993 Sep 1;53(17):4102-4106.

Okuhira M et al. Beta-blocking action of bopindolol, a new beta-blocker, and its active metabolite in open chest dogs. Arch Int Pharmacodyn Ther. 1993 May-Jun;323:5-15.

Koide H, Sasaki T, Tsukumo K, Miyake T, Fuwa T et al. Recognition of an antiparallel beta-sheet structure of human epidermal growth factor by its receptor. Site-directed mutagenesis studies of Ala-30 and Asn-32. FEBS Lett. 1992 May 4;302(1):39-42.

Koide H, Tsukumo K, Sasaki T, Oka T, Miyake T, Fuwa T et al. A site-detected mutagenesis study on the role of isoleucine-23 of human epidermal growth factor in the receptor binding. Biochim Biophys Acta. 1992 Apr 17;1120(3):257-261.

Kato Y, Fuwa T et al. Existence of two pathways for the endocytosis of epidermal growth factor by rat liver: phenylarsine oxide-sensitive and -insensitive pathways. Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8507-8511.

Ito M, Kyo E et al. Growth inhibition of transforming growth factor beta on human gastric carcinoma cells: receptor and postreceptor signaling. Cancer Res. 1992 Jan 15;52(2):295-300.

Shioi A, Suzuki H et al. Interleukin 4 inhibits murine osteoclast formation in vitro. J Cell Biochem. 1991 Nov;47(3):272-277.

Kyo E. Inhibition of 3H-TdR uptake for human gastric carcinoma cells by epidermal growth factor specific antibody. Hiroshima J Med Sci. 1991 Mar;40(1):15-21.

Kiyohara Y, Fuwa T et al. Improvement in wound healing by epidermal growth factor (EGF) ointment. II. Effect of protease inhibitor, nafamostat, on stabilization and efficacy of EGF in burn. J Pharmacobiodyn. 1991 Jan;14(1):47-52.

Kajikawa K, Sumiyoshi H et al. Expression of epidermal growth factor in human tissues. Immunohistochemical and biochemical analysis. Virchows Arch A Pathol Anat Histopathol. 1991;418(1):27-32.

Takekura N, Kyo E et al. Effects of tyrosine kinase inhibitor, erbstatin, on cell growth and growth-factor/receptor gene expression in human gastric carcinoma cells. Int J Cancer. 1991 Apr 1;47(6):938-942.

Murakami T, Amagase H, Fuwa T et al. Enhanced rectal and nasal absorption of human epidermal growth factor by combined use of the absorption promoter and the synthetic polymer in rats. Eur J Drug Metab Pharmacokinet. 1991;Spec No 3:125-131.

Yanai S, Fuwa T et al. Kinetic analysis of receptor-mediated endocytosis of epidermal growth factor by isolated rat hepatocytes. Am J Physiol. 1991 Mar;260(3 Pt 1):C457-C467.

Hatono S, Yatsunami T, Fuwa T et al. Absorption, biliary excretion, and metabolism of a new cholelitholytic agent, ursodeoxycholyl N-carboxymethylglycine and its esters in rats. J Pharmacobiodyn. 1991 Oct;14(10):561-566.

Sumiyoshi H et al. Heterogenicity of ornithine decarboxylase during mouse colon carcinogenesis and in human colon tumors. Cancer Res. 1991 Apr 15;51(8):2069-2072.

Ito M, Kyo E et al. Expression of several growth factors and their receptor genes in human colon carcinomas. Virchows Arch B Cell Pathol Incl Mol Pathol. 1990;59(3):173-178.

Okumura K, Fuwa T et al. Improvement in wound healing by epidermal growth factor (EGF) ointment. I. Effect of nafamostat, gabexate, or gelatin on stabilization and efficacy of EGF. Pharm Res. 1990 Dec;7(12):1289-1293.

Amagase H, Hashimoto K, Fuwa T et al. Possible mechanism of gastric mucosal protection by epidermal growth factor in rats. Life Sci. 1990;47(14):1203-1211.

Amagase H, Ushijima M, Fuwa T et al. Protective effect of human epidermal growth factor against the experimental gastric mucosal lesions in rats. Life Sci. 1990;47(12):1031-1036.

Yoshida K, Kyo E et al. EGF and TGF-alpha, the ligands of hyperproduced EGFR in human esophageal carcinoma cells, act as autocrine growth factors. Int J Cancer. 1990 Jan 15;45(1):131-135.

Amagase H, Tamura K, Okuhira M, Kakimoto M, Amano H, Hashimoto K, Fuwa T et al. Epidermal growth factor prolongs survival time of tumor-bearing mice. Jpn J Cancer Res. 1990 May;81(5):495-500.

Yoshida K, Kyo E et al. Expression of epidermal growth factor, transforming growth factor-alpha and their receptor genes in human gastric carcinomas; implication for autocrine growth. Jpn J Cancer Res. 1990 Jan;81(1):43-51.

Amagase H, Tamura K, Hashimoto K, Fuwa T et al. Response of A431 experimental human solid xenograft to mitomycin C in combination with human epidermal growth factor in mice. J Pharmacobiodyn. 1990 Apr;13(4):263-268.

Cooke RM, Miyake T, Fuwa T et al. Nuclear-magnetic-resonance studies of human epidermal growth factor. Eur J Biochem. 1990 Nov 13;193(3):807-815.

Sato H, Fuwa T et al. Internalization of EGF in perfused rat liver is independent of the degree of receptor occupancy. Am J Physiol. 1990 May;258(5 Pt 1):G682-G689.

Yanai S, Fuwa T et al. Kinetic analysis of the downregulation of epidermal growth factor receptors in rats in vivo. Am J Physiol. 1990 Apr;258(4 Pt 1):C593-C598.

Ohshita Y et al. A point mutation in norA gene is responsible for quinolone resistance in Staphylococcus aureus. Biochem Biophys Res Commun. 1990 Nov 15;172(3):1028-1034.

Yoshida K, Kyo E et al. Epidermal growth factor induces the expression of its receptor gene in human gastric carcinoma cell line TMK-1. Jpn J Cancer Res. 1989 Aug;80(8):743-746.

Kim DC, Fuwa T et al. Kinetic analysis of the elimination process of human epidermal growth factor (hEGF) in rats. Biochem Pharmacol. 1989 Jan 15;38(2):241-249.

Sato H, Fuwa T et al. Decrease in the number of receptors for epidermal growth factor in the liver of D-galactosamine-intoxicated rats. Biochem Pharmacol. 1989 Aug 15;38(16):2663-2671.

Murakami T, Amagase H, Fuwa T et al. Down-regulation and its effect of epidermal growth factor receptors on the pharmacokinetics of human epidermal growth factor after i.v. administration in rats. Int J Pharmaceutics. 1989 Sep 15;54(3):259-267.

Ishii Y, Fuwa T et al. Preparation of EGF labeled liposomes and their uptake by hepatocytes. Biochem Biophys Res Commun. 1989 Apr 28;160(2):732-736.

Hayashi T, Hashimoto K, Sakamoto S. A sensitive enzyme immunoassay for human epidermal growth factor. Determination of hEGF in human serum and urine and pharmacokinetics in mouse. J Pharmacobiodyn. 1989 Jul;12(7):410-415.

Amagase H, Kakimoto M, Hashimoto K, Fuwa T et al. Epidermal growth factor receptor-mediated selective cytotoxicity of antitumor agents toward human xenografts and murine syngeneic solid tumors. Jpn J Cancer Res. 1989 Jul;80(7):670-678.

Kohda D, Miyake T, Fuwa T et al. Polypeptide chain fold of human transforming growth factor alpha analogous to those of mouse and human epidermal growth factors as studied by two-dimensional 1H NMR. Biochemistry. 1989 Feb 7;28(3):953-958.

Hayashi T, Sakamoto S et al. HPLC analysis of human epidermal growth factor using immunoaffinity precolumn. II. Determination of hEGF in biological fluids. Chromatographia. 1989 Jun;27(11):574-580.

Hayashi T, Sakamoto S et al. HPLC analysis of human epidermal growth factor using immunoaffinity precolumn. I. Optimization of immunoaffinity column. Chromatographia. 1989 Jun;27(11):569-573.

Murakami T, Amagase H, Hayashi T, Fuwa T et al. Biliary and urinary excretions of immunoreactive human epidermal growth factor after intravenous administration in rats. Int J Pharmaceutics. 1989 Jan 15;49(2):173-178.

Imanishi K, Kyo E, Hozumi T et al. Inhibition of growth of human lung adenocarcinoma cell lines by anti-transforming growth factor-alpha monoclonal antibody. J Natl Cancer Inst. 1989 Feb 1;81(3):220-223.

Araki F, Nakamura H, Nojima N, Tsukumo K, Sakamoto S. Stability of recombinant human epidermal growth factor in various solutions. Chem Pharm Bull (Tokyo). 1989 Feb;37(2):404-406.

鳩野俊三, 奥平正泰, 橋本健, 矢崎明, 横本正治, 不破亨ほか. 胆汁酸をキャリアとした新規制癌剤CA102. Drug Delivery System. 1989;3(3):445-449.

Sato H, Sakamoto S, Fuwa T et al. Dynamic determination of kinetic parameters for the interaction between polypeptide hormones and cell-surface receptors in the perfused rat liver by the multiple-indicator dilution method. Proc Natl Acad Sci U S A. 1988 Nov;85(21):8355-8359.

Fujiki H, Uda N et al. Diarrhetic shellfish toxin, dinophysistoxin-1, is a potent tumor promoter on mouse skin. Jpn J Cancer Res. 1988 Oct;79(10):1089-1093.

Murakami T, Amagase H, Hayashi T, Nojima N, Fuwa T et al. Intravenous and subcutaneous pharmacokinetics and rectal bioavailability of human epidermal growth factor in the presence of absorption promoter in rat. Int J Pharmaceutics. 1988 Sep;46(1-2):9-17.

Hayashi T, Sakamoto S, Fuwa T et al. Determination of epidermal growth factors in human urine by high performance liquid chromatography using anti-hEGF antibody precolumn. Anal Sci. 1988 Jun 26;4:313-316.

Hayashi T, Sakamoto S. Radioimmunoassay of human epidermal growth factor--hEGF levels in human body fluids. J Pharmacobiodyn. 1988 Mar;11(3):146-151.

Kim DC, Fuwa T et al. Kinetic analysis of in vivo receptor-dependent binding of human epidermal growth factor by rat tissues. J Pharm Sci. 1988 Mar;77(3):200-207.

Yachi K, Fuwa T et al. Comparison of specific binding of human epidermal growth factor (EGF) to sinusoidal and bile canalicular membranes isolated from rat liver. J Biochem. 1988 Mar;103(3):448-451.

Yasui W, Sumiyoshi H et al. Interaction between epidermal growth factor and gastrin on DNA synthesis of the gastrointestinal mucosa in rats. Hiroshima J Med Sci. 1988 Mar;37(1):1-6.

Yasui W, Sumiyoshi H et al. Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res. 1988 Jan 1;48(1):137-141.

Noda Y, Kato K, Hayashi T et al. Immunohistochemical localization by monoclonal antibody of human epidermal growth factor in mixed tumors of the skin. J Cutan Pathol. 1987 Dec;14(6):337-342.

Mori M, Hayashi T, Kato K et al. Immunohistochemical distribution of human epidermal growth factor in salivary gland tumors. Virchows Arch A Pathol Anat Histopathol. 1987;411(6):499-507.

Oda N, Sakamoto S et al. Purification and characterization of phospholipase A2 from Trimeresurus gramineus venom. J Biochem. 1987 Dec;102(6):1441-1449.

Makino K, Sakamoto S et al. Proton nuclear magnetic resonance study on the solution conformation of human epidermal growth factor. Proc Natl Acad Sci U S A. 1987 Nov;84(22):7841-7845.

Imada O, Hayashi N, Masamoto K, Kasuga S, Fuwa T, Nakagawa S. Long-latency growth-promoting activity of EGF when administered to mice at the neonatal stage. Am J Physiol. 1987 Sep;253(3 Pt 1):E251-E254.

Hayashi T, Sakamoto S, Fuwa T et al. Determination of human epidermal growth factors in cultured media of Escherichia coli by high performance liquid chromatography. Anal Sci. 1987;3(5):445-448.

Tsukitani K, Hayashi T, Kato K et al. Immunohistochemical detection of human epidermal growth factor in submandubular glands and their tumors using a polyclonal antiserum and monoclonal antibody. Histochemistry. 1987;87(4):293-300.

Yoshida S, Kasuga S, Hirao Y, Fuwa T, Nakagawa S. Effect of biosynthetic human epidermal growth factor on the synthesis and secretion of mucin glycoprotein from primary culture of rabbit fundal mucosa cells. In Vitro Cell Dev Biol. 1987 Jul;23(7):460-464.

Tsukumo K, Nakamura H, Sakamoto S. Purification and characterization of high molecular weight human epidermal growth factor from human urine. Biochem Biophys Res Commun. 1987 May 29;145(1):126-133.

佐藤博章, 坂本俊治, 不破亨ほか. 上皮成長因子(EGF)受容体の肝細胞表面における挙動‐肝灌流法を用いた速度論的解析-. 薬物動態. 1987;2(4):366-367.

柳井薫雄, 坂本俊治, 不破亨ほか. ラット遊離肝細胞を用いたヒト上皮細胞増殖因子とその受容体の相互作用の速度論的解析. 薬物動態. 1987;2(4):368-369.

Yanai S, Fuwa T et al. Binding of human epidermal growth factor to tissue homogenates of the rat. Chem Pharm Bull (Tokyo). 1987 Dec;35(12):4891-4897.

Yasui W, Sumiyoshi H et al. Expression of Ha-ras oncogene product in rat gastrointestinal carcinomas induced by chemical carcinogens. Acta Pathol Jpn. 1987 Nov;37(11):1731-1741.

林奉権ほか. 自動試料前処理装置を用いる血しょう中のアドリアマイシン及びその代謝産物の高速液体クロマトグラフィーによる定量. 分析化学. 1986;35(3):230-235.

金東出, 不破亨ほか. ヒト上皮細胞増殖因子(EGF)のラットにおける体内動態の速度論的解析. 薬物動態. 1986;1(3):256-257.

Yasui W, Sumiyoshi H et al. Gut endocrine cells in rat stomach carcinoma induced by N-methyl-N'-nitro-N-nitrosoguanidine. J Cancer Res Clin Oncol. 1986;111(2):87-92.

Yasui W, Sumiyoshi H et al. Cholecystokinin inhibition of tumor growth and gastrin-stimulated cyclic adenosine 3':5'-monophosphate metabolism in human gastric carcinoma in nude mice. Cancer Res. 1986 Feb;46(2):740-743.

Akiyama H, Sumiyoshi H et al. Carcinoembryonic antigen (CEA) in gallbladder bile and mucosa in cholecystolithiasis. Acta Chir Scand. 1986 Aug-Sep;152:509-513.

Yatsunami T, Yamamoto H, Nomiyama J et al. Synthesis and antibacterial action of sarcotoxin ia and its analogs, a bactericidal protein from haemolmph of Sarcophaga perigrina Larvae. Peptide Chemistry, Proceedings of the 24th Symposium on Peptide Chemistry. 1986;157-162.

Arakawa M, Oka T et al. Further characterization of the inhibition of casein production in a primary mouse mammary epithelial cell culture by epidermal growth factor. Antagonism by cyclic AMP. Exp Cell Res. 1985 May;158(1):111-118.

Nakagawa S, Yoshida S, Hirao Y, Kasuga S, Fuwa T. Biological effects of biosynthetic human EGF on the growth of mammalian cells in vitro. Differentiation. 1985;29(3):284-288.

Yasui W, Sumiyoshi H et al. Calcium-activated, phospholipid-dependent protein kinase in human gastric mucosa and carcinoma. Jpn J Cancer Res. 1985 Dec;76(12):1168-1173.

Ochiai A, Kyo E, Hozumi T et al. A monoclonal antibody reacting with various human carcinomas and fetal colon and esophagus. Jpn J Cancer Res. 1985 Oct;76(10):915-918.

Yasui W, Sumiyoshi H et al. Type I and II cyclic adenosine 3':5'-monophosphate-dependent protein kinase in human gastric mucosa and carcinomas. Cancer Res. 1985 Apr;45(4):1565-1568.

Ohnishi M, Sugimoto H et al. Water-soluble carrier proteins having carboxyl spacer groups. Chem Pharm Bull. 1985;33(7):2871-2876.

Ohnishi M, Sugimoto H et al. Heterobifunctional reagents for cross-linking of sugar with protein. Chem Pharm Bull. 1985;33(2):674-678.

鳩野俊三ほか. 胆汁酸の代謝（第14報）サルコシン抱合胆汁酸. 薬学雑誌. 1984;104(5):466-471.

Kimura M, Hatono S et al. Synthesis, intestinal absorption and metabolism of sarcosine conjugated ursodeoxycholic acid. Steroids. 1984 Jun;43(6):677-687.

Ohno S, Yazaki A. Simple construction of human c-myc gene implicated in B-cell neoplasmas and its relationship with avian v-myc and human lympholines. Scand J Immunol. 1983 Nov;18(5):373-388.

Yazaki A, Ohno S. Recurrence of 49-base decamers, nonomers, and octamers within mouse C mu gene of Ig heavy chain and its primordial building block. Proc Natl Acad Sci U S A. 1983 Apr;80(8):2337-2340.

Ardalan B, Arakawa M et al. Effect of L-glutamine antagonists on 5-phosphoribosyl 1-pyrophosphate levels in P388 leukemia and in murine colon adenocarcinomas in vivo. Biochem Pharmacol. 1982 Apr 15;31(8):1509-1513.

Tabushi I, Yazaki A. P-450-type dioxygen activation using hydrogen/colloidal platinum as an effective electron donor. J Am Chem Soc. 1981 Dec 1; 103(24):7371-7373.

Tabushi I, Yazaki A. N-alkyl-4,4'-bipyridyl. A new efficient electron carrier in the photochemical hydrogen producing system. Tetrahedron. 1981;37(24):4185-4188.

Tabushi I, Yazaki A. Effective hydrogen generation system by use of ascorbic acid as a reversible electron donor. J Org Chem. 1981 Apr 1;46(9):1899-1901.

Tabushi I, Yazaki A et al. Artificial photosynthesis system of bacteria type. Tetrahedron Lett. 1980;21(4):373-376.

Okumura K, Arakawa M et al. Tissue distribution and metabolism of drugs VI: Effect of second drugs on pancreatic distribution and insulin-releasing activity of sulfonylureas in perfused rat pancreas. J Pharm Sci. 1980 Feb;69(2):157-159.

Arakawa M et al. Tissue distribution and metabolism of drugs V: Effect of secretin and pancreozymin on drug transport in rabbit pancreas. J Pharm Sci. 1980 Jan;69(1):27-30.

Besso H et al. Reactions of 4H-pyran-4-thiones with ammonia, hydrazine, and guanidine. Bull Chem Soc Jpn. 1978 Jan;51(1):179-181.

Besso H et al. Tautomerism of 4-pyridones. Bull Chem Soc Jpn. 1977 Mar;50(3):710-712.

Besso H et al. Substituent effects on dissociation constants of trans-3-hydroxy-6-styryl-4-pyrones. Bull Chem Soc Jpn. 1977 Aug;50(8):2161-2163.

Besso H et al. Substituent effects on tautomerism of 4-pyridinethiones. Bull Chem Soc Jpn. 1977 Dec;50(12):3295-3297.